Evidence map›Paper›PMID 34353802›Full record

ArticleBMJ open2021

Procalcitonin-guided initiation of antibiotics in AECOPD inpatients: study protocol for a multicenter randomised controlled trial.

Lixue Huang, Jinxiang Wang, Xiaoying Gu, Weili Sheng, Yeming Wang, Bin Cao

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04682899 (Procalcitonin-guided Initiation of Antibiotics in AECOPD Inpatients), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04682899 phase3unknown statusnot on this map

Procalcitonin-guided Initiation of Antibiotics in AECOPD Inpatients: a Multicenter Randomized Controlled Trial

TypeinterventionalSponsorCapital Medical UniversityRan2021 to 2022Enrolled500ConditionsProcalcitonin, Chronic Obstructive Pulmonary DiseaseArmsprocalcitonin-guided antibiotic therapy, guideline-guided antibiotic therapy
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lixue HuangDepartment of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, China.ORCID 0000-0002-9110-9436
Jinxiang WangDepartment of Pulmonary and Critical Care Medicine,Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Xiaoying GuDepartment of Pulmonary and Critical Care Medicine,National Center for Respiratory Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China.
Weili ShengDepartment of Pulmonary and Critical Care Medicine, Daxing teaching hospital of Capital Medical University, Beijing, China.
Yeming WangDepartment of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, China.
Bin CaoDepartment of Pulmonary and Critical Care Medicine, Capital Medical University, Beijing, China caobin_ben@163.com.
Capital Medical University · CNBeijing Luhe Hospital Affiliated to Capital Medical University · CNChina-Japan Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCurrent antibiotic prescription for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is generally based on the Anthonisen criteria in The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guideline that have a potential risk of antibiotics overuse. The dilemma is to identify patients who are most likely to benefit from antibiotics while avoiding unnecessary antibiotic use. Procalcitonin (PCT), a more sensitive and specific biomarker of bacterial infection than other conventional laboratory tests, has the potential to determine those patients in whom antibiotics would be beneficial. It is unclear whether PCT-guided antibiotic therapy is safe and effective for patients hospitalised with AECOPD. The study hypothesis is that PCT-guided antibiotic therapy could reduce the antibiotic prescription rate for AECOPD, compared with the GOLD guideline recommendations, without negatively impacting the treatment success rate. METHODS AND ANALYSIS: In this multicenter, open-label, randomised controlled trial, we aim to enrol 500 hospitalised patients with AECOPD that will be randomly assigned to either a PCT-guided group or a GOLD guideline-guided group. The coprimary endpoints are antibiotic prescription rate for AECOPD within 30 days post randomisation and treatment success rate at day 30 post randomisation. The secondary outcomes include: antibiotic prescription rate at day 1 post randomisation; hospital antibiotic exposure; length of hospital stay; rate of subsequent exacerbation and hospital readmission; overall mortality within 30 days post randomisation; changes in lung function and the score of COPD assessment test and modified Medical Research Council; and rate of intensive care unit admission. ETHICS AND DISSEMINATION: This trial has been approved by the ethic committee of China-Japan Friendship Hospital. The findings of the study will be disseminated in peer-reviewed journals. If the results of the study are positive, PCT-guided antibiotic therapy is likely to change the guidelines for antibiotic recommendations for patients with AECOPD. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT04682899.

Indexed as

Bacterial InfectionsPulmonary Disease, Chronic ObstructiveAnti-Bacterial AgentsHumansInpatientsMulticenter Studies as TopicProcalcitoninRandomized Controlled Trials as TopicAnti-Bacterial AgentsProcalcitoninclinical trialsprimary careprotocols & guidelinesthoracic medicine

Identifiers

PMID34353802
PMCPMC8344287
OpenAlexW3189858729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.